Evidence map›Paper›PMID 42141135›Full record

ArticleCommunications biology2026

Regulation of the PKD2 channel function and associated disease phenotypes by RASSF4.

Rui Tian, Wanyi Fang, Wenbin Yuan, Shi Li, Yixin Wu, Xueying Dong, Wei Liu, Jinghua Kong, Xiaoling Deng, Rui Zhang and 9 more

Abstract read
In one paragraph

Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Rui Tian *National "111" Center for Cellular Regulation and Molecular Pharmaceutics, School of Life and Health Sciences, Hubei University of Technology, Wuhan, China.
Wanyi Fang *Membrane Protein Disease Research Group, Department of Physiology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Wenbin YuanNational "111" Center for Cellular Regulation and Molecular Pharmaceutics, School of Life and Health Sciences, Hubei University of Technology, Wuhan, China.
Shi LiNational "111" Center for Cellular Regulation and Molecular Pharmaceutics, School of Life and Health Sciences, Hubei University of Technology, Wuhan, China.
Yixin WuNational "111" Center for Cellular Regulation and Molecular Pharmaceutics, School of Life and Health Sciences, Hubei University of Technology, Wuhan, China.
Xueying DongNational "111" Center for Cellular Regulation and Molecular Pharmaceutics, School of Life and Health Sciences, Hubei University of Technology, Wuhan, China.
Wei LiuNational "111" Center for Cellular Regulation and Molecular Pharmaceutics, School of Life and Health Sciences, Hubei University of Technology, Wuhan, China.
Jinghua KongNational "111" Center for Cellular Regulation and Molecular Pharmaceutics, School of Life and Health Sciences, Hubei University of Technology, Wuhan, China.
Xiaoling DengNational "111" Center for Cellular Regulation and Molecular Pharmaceutics, School of Life and Health Sciences, Hubei University of Technology, Wuhan, China.
Rui ZhangNational "111" Center for Cellular Regulation and Molecular Pharmaceutics, School of Life and Health Sciences, Hubei University of Technology, Wuhan, China.
Hao LyuNational "111" Center for Cellular Regulation and Molecular Pharmaceutics, School of Life and Health Sciences, Hubei University of Technology, Wuhan, China.ORCID http://orcid.org/0000-0002-1634-601X
Shuai XiaoNational "111" Center for Cellular Regulation and Molecular Pharmaceutics, School of Life and Health Sciences, Hubei University of Technology, Wuhan, China.
Dong GuoNational "111" Center for Cellular Regulation and Molecular Pharmaceutics, School of Life and Health Sciences, Hubei University of Technology, Wuhan, China.
Qi ZhangNational "111" Center for Cellular Regulation and Molecular Pharmaceutics, School of Life and Health Sciences, Hubei University of Technology, Wuhan, China.
Declan William AliDepartment of Biological Sciences, University of Alberta, Edmonton, AB, Canada.
Marek MichalakDepartment of Biochemistry, University of Alberta, Edmonton, AB, Canada.ORCID http://orcid.org/0000-0002-9343-9084
Cefan ZhouNational "111" Center for Cellular Regulation and Molecular Pharmaceutics, School of Life and Health Sciences, Hubei University of Technology, Wuhan, China. cefan@hbut.edu.cn.ORCID http://orcid.org/0000-0003-0680-3843
Jingfeng TangNational "111" Center for Cellular Regulation and Molecular Pharmaceutics, School of Life and Health Sciences, Hubei University of Technology, Wuhan, China. Jingfeng_hut@163.com.ORCID http://orcid.org/0000-0002-5524-4518
Xing-Zhen ChenMembrane Protein Disease Research Group, Department of Physiology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada. xzchen@ualberta.ca.ORCID http://orcid.org/0000-0003-4464-0598

Funding

Kidney Foundation of Canada (La Fondation canadienne du rein) 2020KHRG-673101Kidney Foundation of Canada (La Fondation canadienne du rein) RGPIN-2019-05953
6 · The paper itself

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common monogenic genetic disorders, caused by mutations in receptor PKD1 or ion channel PKD2, and is characterized by progressive renal cyst development with additional hepatic and extrarenal manifestations. As effective treatments for ADPKD remain limited, further investigation into the function and regulation of PKD proteins is needed. Using biotin-based proximity labeling combined with mass spectrometry in human embryonic kidney (HEK) cells, here we identify Ras association domain family member 4 (RASSF4) as a potential PKD2-interacting protein. The association between PKD2 and RASSF4 is validated by co-immunoprecipitation, bimolecular fluorescence complementation, and in vitro binding assays in HEK cells and mouse kidneys. Functional analyses using two-electrode voltage clamp electrophysiology in Xenopus oocytes demonstrate that RASSF4 enhances PKD2 channel activity without affecting its membrane expression. In vivo studies in larval zebrafish show that RASSF4 over-expression alleviates, whereas Rassf4 knockdown exacerbates, Pkd2 knockdown-associated phenotypes, including tail curling, pronephric cyst formation, renal filtration defects, and motor dysfunction. Disruption of the RASSF4/PKD2 interaction using a blocking peptide (amino acid P134-S168) abolishes RASSF4-mediated stimulation of PKD2 channel function and phenotypic rescue, while worsening disease severity, likely by interfering with endogenous complex formation. Mechanistically, RASSF4 enhances the functionally critical intramolecular interaction between the PKD2 N- and C-termini and suppresses RAS/MAPK signaling in HEK cells. Together, these findings identify RASSF4 as a PKD2 regulator and suggest that the RASSF4/PKD2 complex represents a potential therapeutic target for ADPKD.

Indexed as

Polycystic Kidney, Autosomal DominantTRPP Cation ChannelsZebrafish ProteinsAnimalsHEK293 CellsHumansKidneyMicePhenotypeZebrafishPKD2 protein, zebrafishTRPP Cation ChannelsZebrafish Proteins

Identifiers

PMID42141135
PMCPMC13434659

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.